A promising new approach to treating multiple sclerosis is remyelination: That is, replenishing the fatty sheath surrounding nerve cells that degenerate in this autoimmune disease.
Biogen is testing a drug that can restore the myelin sheaths, but San Diego startup Novoron Bioscience is also making headway in this effort to remyelinate the nerve cells.
It just landed a $680,000 SBIR grant from the National Institutes of Health to expand its preclinical work over the course of two years.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Multiple sclerosis worsens as the body’s nerve cells deconstruct. Novoron’s lead compound, NOVO-117, targets a molecule called RhoA that has been found to inhibit the body’s natural remyelination process using oligodendrocyte precursor cells. The startup’s idea is to help excite nerve regeneration.
While the most recent funding is to push forward the drug’s application in multiple sclerosis, the company is also pursuing related therapeutics for glaucoma and spinal cord injury.
[Image courtesy of Flickr user LeeAnder]
